InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,219.84
(
0.11%
)
US TECH 100
17,660.72
(
0.11%
)
Dow Jones
39,485.78
(
0.25%
)
Brent Oil
83.80
(
-0.18%
)
Bitcoin
61,096.00
(
-3.10%
)
Post# of 8449
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Green Money 00

Send PM Follow Ignore
Followers 446
Posts 31415
Boards Moderated 4
Alias Born 04/04/2006

Green Money 00

Re: None

Thursday, 03/10/2016 8:27:14 AM

Thursday, March 10, 2016 8:27:14 AM

Post# of 8449
4:59 am XOMA halts gevokizumab related development; prelim data did not show intended results; initiates asset sales process (XOMA) :

Co provided an update for its Gevokizumab

Given XOMA's focus on endocrinology, the Company has decided to stop all gevokizumab related development activities and is initiating a formal sales process for the asset. As a result, the Company is closing the Phase 3 program in patients suffering from pyoderma gangrenosum.
A preliminary review of the data from the ~25 patients enrolled in the trial to date did not show a clear signal of activity in this indication.
XOMA has been approached by several companies interested in gevokizumab and data from all gevokizumab studies will be available to potential buyers.

YOU agree to all this when reading my posts

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114785639

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=114785652

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up